The Brain Tumor Awareness Month (BTAM) that runs in May is designed to raise awareness about the serious condition that afflicts approximately 35,000 people each year in the U.S., according to the National Cancer Institute. Glioblastoma multiforme (GBM) is one of the most common and aggressive forms of the disease that progresses rapidly, resulting in poor prognosis for those patients. It represents a significant unmet need and a number of biopharmaceutical companies are developing therapies in that area.